EPO‐INT‐3.

Methods	randomized controlled trial, placebo‐controlled
Participants	n = 200, breast, Non‐Hodgkin lymphoma, multiple myeloma, ovarian, small cell lung cancer, other cancer; concomitant treatment: chemotherapy
Interventions	drug = Epoetin alpha dose = 150 IU/kg sc TIW hb‐target = 12‐14 g/dL (women), 14‐16 g/dL (men) planned ESA duration = 12 weeks
Outcomes	Primary: Transfusion; secondary: Hb, QoL
Notes	study number = 36274
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	according to randomization schedule prepared by RWJPRI
Allocation concealment?	Low risk	central randomization